Barnidipine (hydrochloride)
(Synonyms: 盐酸巴尼地平,YM 09730-5) 目录号 : GC13289A calcium channel blocker
Cas No.:104757-53-1
Sample solution is provided at 25 µL, 10mM.
Barnidipine is a calcium-channel blocker.
A calcium channel, an ion channel which displays selective permeability to calcium ions, is sometimes synonymous as voltage-dependent calcium channel, although there are also ligand-gated calcium channels.
In vitro: The effects of barnidipine on L-type Ca(2+) current (I(Ca(L))) were investigated in rat ventricular cardiomyocytes. It was found that barnidipine reduced I(Ca(L)) in a concentration and voltage dependent manne. Barnidipine induced a leftward shift of the steady-state inactivation curve of I(Ca(L)) [1].
In vivo: A previous study was conducted to investigate the influence of barnidipine treatment on early stage hypertension by determining the mesenteric and renal arteries as well as the kidney in L-NAME-induced hypertensive rats. Barnidipine was applied to rats after 2 weeks of L-NAME administration, and continued for the next 3 weeks concomitantly with L-NAME. Histopathological studies verified structural alterations in the arteries and the kidney. Moreover, a decrease in endothelial nitric oxide synthase expression was observed both in the arteries and kidney of hypertensive rats with barnidipine treatment [2].
Clinical trial: In patients with hypertension and type 2 diabetes mellitus, it was found that barnidipine treatment led to a significant reduction in blood pressure. Data recorded with ABPM also showed a similar trend. Barnidipine + losartan could reduce the levels of Hs-CRP, TNF-α, sVCAM-1, sICAM-1, and isoprostanes [3].
References:
[1] Wegener JW, Meyrer H, Rupp J, Nawrath H. Barnidipine block of L-type Ca(2+) channel currents in rat ventricular cardiomyocytes. Br J Pharmacol. 2000 Aug;130(8):2015-23.
[2] Alp Yildirim FI, Eker Kizilay D, Ergin B, Balci Ekmeki, Topal G, Kucur M, Demirci Tansel C, Uyde Doan BS. Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats. Eur J Pharmacol. 2015 Oct 5;764:433-42.
[3] Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P. Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. BMC Cardiovasc Disord. 2016 Apr 12;16:66.
Cas No. | 104757-53-1 | SDF | |
别名 | 盐酸巴尼地平,YM 09730-5 | ||
化学名 | (4S)-3,5-pyridinedicarboxylic acid, 3-methyl 5-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl] ester, monohydrochloride | ||
Canonical SMILES | CC1=C(C(O[C@@H]2CN(CC3=CC=CC=C3)CC2)=O)[C@H](C(C(OC)=O)=C(C)N1)C4=CC([N+]([O-])=O)=CC=C4.Cl | ||
分子式 | C27H29N3O6 • HCl | 分子量 | 528.0 |
溶解度 | ≥ 16.3mg/mL in DMSO with gentle warming | 储存条件 | 4°C, away from moisture and light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.8939 mL | 9.4697 mL | 18.9394 mL |
5 mM | 0.3788 mL | 1.8939 mL | 3.7879 mL |
10 mM | 0.1894 mL | 0.947 mL | 1.8939 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet